Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATRA
  • CUSIP: N/A
  • Web:
  • Market Cap: $446.16 million
  • Outstanding Shares: 30,559,000
Average Prices:
  • 50 Day Moving Avg: $15.53
  • 200 Day Moving Avg: $15.23
  • 52 Week Range: $11.80 - $23.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $7.39 per share
  • Price / Book: 1.98
  • EBITDA: ($98,030,000.00)
  • Return on Equity: -39.54%
  • Return on Assets: -37.40%
  • Current Ratio: 19.38%
  • Quick Ratio: 19.38%
  • Average Volume: 181,998 shs.
  • Beta: 1.38
  • Short Ratio: 19.04

Frequently Asked Questions for Atara Biotherapeutics (NASDAQ:ATRA)

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.94) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.05. View Atara Biotherapeutics' Earnings History.

When will Atara Biotherapeutics make its next earnings announcement?

Atara Biotherapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Atara Biotherapeutics.

Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2017?

5 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their forecasts range from $10.00 to $47.00. On average, they expect Atara Biotherapeutics' share price to reach $26.75 in the next year. View Analyst Ratings for Atara Biotherapeutics.

What are analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (8/28/2017)
  • 2. Canaccord Genuity analysts commented, "Jounce announced initiation of the Phase 2 portion of the ICONIC study of JTX-2011." (4/21/2017)

Who are some of Atara Biotherapeutics' key competitors?

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:

  • Isaac E. Ciechanover M.D., Chairman of the Board, President, Chief Executive Officer
  • John F. McGrath Jr., Chief Financial Officer, Executive Vice President
  • Joseph Newell, Executive Vice President, Chief Technical Operations Officer
  • Christopher M. Haqq M.D. Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Heather D. Turner, Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy
  • Mitchall G. Clark, Executive Vice President and Chief Regulatory and Quality Assurance Officer
  • Gad Soffer, Executive Vice President and Chief Strategy Officer
  • Kanya Rajangam M.D. Ph.D., Senior Vice President, Chief Medical Officer
  • Carol G. Gallagher Pharm.D., Lead Independent Director
  • Eric L. Dobmeier, Independent Director

How do I buy Atara Biotherapeutics stock?

Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of Atara Biotherapeutics stock can currently be purchased for approximately $14.60.

MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $26.75 (83.22% upside)
Consensus Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)
Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)
Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Goldman Sachs Group IncReiterated RatingNeutral -> Neutral$20.00N/AView Rating Details
10/5/2017Jefferies Group LLCReiterated RatingBuy$30.00N/AView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$47.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
3/16/2017Citigroup Inc.Set Price TargetSell$10.00HighView Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$40.00 -> $34.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)
Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Earnings History by Quarter for Atara Biotherapeutics (NASDAQ ATRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017($0.97)N/AView Earnings Details
8/7/2017Q2 2017($0.89)($0.94)ViewN/AView Earnings Details
3/9/201712/31/2016($0.98)($0.63)ViewN/AView Earnings Details
11/4/2016Q3 2016($0.79)($0.88)ViewN/AView Earnings Details
8/8/2016Q2($0.61)($0.66)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
3/3/2016Q4 2015($0.48)($0.75)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.42)($0.43)ViewN/AView Earnings Details
2/26/2015Q4 2014($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)
2017 EPS Consensus Estimate: ($3.86)
2018 EPS Consensus Estimate: ($3.93)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.78)($0.75)($0.77)
Q2 20172($0.92)($0.91)($0.92)
Q3 20172($1.10)($0.95)($1.03)
Q4 20172($1.32)($0.98)($1.15)
Q1 20181($1.00)($1.00)($1.00)
Q2 20181($1.00)($1.00)($1.00)
Q3 20181($1.02)($1.02)($1.02)
Q4 20181($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)


Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Ownership Percentage: 16.20%
Institutional Ownership Percentage: 82.95%
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Christopher HaqqEVPSell6,000$14.35$86,100.00View SEC Filing  
10/12/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00View SEC Filing  
10/11/2017Isaac E CiechanoverCEOSell2,200$15.25$33,550.00View SEC Filing  
9/20/2017Isaac E CiechanoverCEOSell4,400$15.54$68,376.00View SEC Filing  
9/15/2017Christopher HaqqEVPSell6,000$15.30$91,800.00View SEC Filing  
9/7/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00View SEC Filing  
8/23/2017Isaac E CiechanoverCEOSell4,400$13.54$59,576.00View SEC Filing  
8/16/2017Carol Giltner GallagherDirectorSell1,184$14.30$16,931.20View SEC Filing  
8/16/2017John McgrathCFOSell4,200$14.31$60,102.00View SEC Filing  
8/16/2017Mitchall G. ClarkEVPSell3,021$14.33$43,290.93View SEC Filing  
8/15/2017Christopher HaqqEVPSell7,604$14.75$112,159.00View SEC Filing  
8/11/2017Isaac E CiechanoverCEOSell4,400$14.67$64,548.00View SEC Filing  
7/25/2017Isaac E CiechanoverCEOSell5,500$16.49$90,695.00View SEC Filing  
7/24/2017Isaac E CiechanoverCEOSell2,800$16.94$47,432.00View SEC Filing  
7/17/2017Christopher HaqqEVPSell6,000$14.92$89,520.00View SEC Filing  
6/15/2017Christopher HaqqEVPSell6,000$12.65$75,900.00View SEC Filing  
6/9/2017Carol Giltner GallagherDirectorSell1,000$13.15$13,150.00View SEC Filing  
5/31/2017Isaac E CiechanoverCEOSell6,900$13.35$92,115.00View SEC Filing  
5/30/2017Isaac E CiechanoverCEOSell3,450$13.44$46,368.00View SEC Filing  
5/18/2017Isaac E CiechanoverCEOSell4,800$14.91$71,568.00View SEC Filing  
5/16/2017Carol Giltner GallagherDirectorSell1,184$15.25$18,056.00View SEC Filing  
5/16/2017Gad SofferEVPSell12,674$15.16$192,137.84View SEC Filing  
5/16/2017John McgrathCFOSell4,000$15.11$60,440.00View SEC Filing  
4/26/2017Isaac E CiechanoverCEOSell7,200$17.56$126,432.00View SEC Filing  
4/25/2017Isaac E CiechanoverCEOSell3,600$17.33$62,388.00View SEC Filing  
4/17/2017Christopher HaqqEVPSell6,000$17.28$103,680.00View SEC Filing  
4/11/2017Isaac E CiechanoverCEOSell7,200$17.03$122,616.00View SEC Filing  
3/28/2017Isaac E CiechanoverCEOSell16,000$20.06$320,960.00View SEC Filing  
3/23/2017John McgrathCFOSell14,000$20.65$289,100.00View SEC Filing  
3/17/2017Isaac E CiechanoverCEOSell30,800$19.38$596,904.00View SEC Filing  
3/10/2017Gad SofferEVPSell2,500$20.00$50,000.00View SEC Filing  
3/10/2017John McgrathCFOSell24,000$20.00$480,000.00View SEC Filing  
2/21/2017John McgrathCFOSell9,000$15.14$136,260.00View SEC Filing  
2/16/2017Carol Giltner GallagherDirectorSell1,183$16.10$19,046.30View SEC Filing  
2/16/2017Isaac E CiechanoverCEOSell4,800$15.56$74,688.00View SEC Filing  
2/16/2017Mitchall G. ClarkEVPSell3,059$15.96$48,821.64View SEC Filing  
2/15/2017Christopher HaqqEVPSell7,604$15.49$117,785.96View SEC Filing  
2/10/2017Gad SofferEVPSell6,274$15.47$97,058.78View SEC Filing  
2/9/2017Christopher HaqqEVPSell13,975$15.46$216,053.50View SEC Filing  
2/3/2017Isaac E CiechanoverCEOSell4,800$13.66$65,568.00View SEC Filing  
1/18/2017Isaac E CiechanoverCEOSell6,000$14.24$85,440.00View SEC Filing  
1/17/2017Christopher HaqqEVPSell6,000$14.27$85,620.00View SEC Filing  
1/6/2017Isaac E CiechanoverCEOSell8,400$16.89$141,876.00View SEC Filing  
12/23/2016Isaac E CiechanoverCEOSell4,800$15.22$73,056.00View SEC Filing  
12/15/2016Christopher HaqqInsiderSell6,000$15.40$92,400.00View SEC Filing  
12/7/2016Isaac E CiechanoverCEOSell7,200$17.93$129,096.00View SEC Filing  
11/23/2016Isaac E CiechanoverCEOSell12,000$18.34$220,080.00View SEC Filing  
11/22/2016Isaac E CiechanoverCEOSell8,400$18.21$152,964.00View SEC Filing  
11/16/2016Carol Giltner GallagherDirectorSell1,184$19.35$22,910.40View SEC Filing  
11/16/2016Gad SofferCOOSell16,718$20.00$334,360.00View SEC Filing  
11/16/2016Mitchall G ClarkInsiderSell2,995$19.53$58,492.35View SEC Filing  
11/14/2016Gad SofferCOOSell9,582$20.55$196,910.10View SEC Filing  
11/11/2016John McgrathCFOSell5,000$19.84$99,200.00View SEC Filing  
10/27/2016Isaac E CiechanoverCEOSell4,800$13.81$66,288.00View SEC Filing  
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.00View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Atara Biotherapeutics (NASDAQ:ATRA)
Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
Loading headlines, please wait.



Atara Biotherapeutics (ATRA) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.